NasdaqCM - Delayed Quote • USD
Compare
At close: 4:00 PM EDT
After hours: 4:14 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Joseph H. Capper | CEO & Director | 1.55M | -- | 1964 |
Mr. Douglas C. Rice CPA | Chief Financial Officer | 470.47k | -- | 1966 |
Mr. William F. Hulse IV | General Counsel & Chief Administrative Officer | 959.59k | -- | 1974 |
Mr. Scott M. Turner | Senior Vice President of Operations & Procurement | 493.98k | -- | 1966 |
Mr. Matthew M. Notarianni | Head of Investor Relations | -- | -- | -- |
Mr. Mark P. Graves | Senior VP & Chief Compliance Officer | -- | -- | 1966 |
Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications | -- | -- | -- |
Ms. Kate Surdez | Chief Human Resources Officer | -- | -- | -- |
Dr. David H. Mason Jr. | Chief Medical Officer | -- | -- | 1947 |
Dr. Robert Benjamin Stein M.D., Ph.D. | President of Regenerative Medicine & Biologics Innovation | 639.28k | -- | 1951 |
MiMedx Group, Inc.
1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770 651 9100 https://www.mimedx.com
- Sector:
- Healthcare
- Industry:
- Full Time Employees:
- 895
Biotechnology
Description
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
Corporate Governance
MiMedx Group, Inc.’s ISS Governance QualityScore as of August 1, 2024 is 5. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 1; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
October 28, 2024 at 10:59 AM UTC - November 1, 2024 at 12:00 PM UTC
MiMedx Group, Inc. Earnings Date
Recent Events
July 31, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
June 7, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
May 24, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
See Full Filing
April 30, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
April 23, 2024 at 12:00 AM UTC
DEFA14A: Proxy Statements
See Full Filing
March 27, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
March 4, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
Related Tickers
CDMO Avid Bioservices, Inc.
11.01
+3.09%
COYA Coya Therapeutics, Inc.
5.12
+2.20%
CORT Corcept Therapeutics Incorporated
33.97
-2.78%
ACET Adicet Bio, Inc.
1.5300
+6.99%
ELYM Eliem Therapeutics, Inc.
6.15
+0.99%
XNCR Xencor, Inc.
16.23
+1.25%
PROK ProKidney Corp.
2.4000
+0.42%
KPTI Karyopharm Therapeutics Inc.
0.8183
-1.89%
NTRB Nutriband Inc.
5.62
-8.02%
COGT Cogent Biosciences, Inc.
9.46
+8.49%